{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"6.4","value":"3.8"},{"groupId":"OG001","lowerLimit":"2.7","upperLimit":"5.6","value":"4.5"},{"groupId":"OG002","lowerLimit":"2.3","upperLimit":"8.0","value":"6.5"},{"groupId":"OG003","lowerLimit":"4.4","upperLimit":"8.1","value":"5.5"},{"groupId":"OG004","lowerLimit":"8.6","upperLimit":"13.3","value":"11.3"},{"groupId":"OG005","lowerLimit":"5.8","upperLimit":"18.0","value":"11.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"55"},{"groupId":"OG004","value":"54"},{"groupId":"OG005","value":"24"}],"units":"Participants"}],"description":"Time to treatment failure is defined as the time from study entry to the date patients end treatment.Time to treatment failure will be evaluated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Endometrial Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Ovarian Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Hepatocellular Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Carcinoid Cohort"},{"description":"Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Islet Cell (Double Agent) Cohort"},{"description":"Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG005","title":"Islet Cell (Bevacizumab-only) Cohort"}],"paramType":"MEDIAN","populationDescription":"All patients that began study treatment were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Time from study entry to the date patients end treatment, assessed up to 3 years","title":"Time to Treatment Failure","type":"SECONDARY","unitOfMeasure":"months"}